EGFR mutations correlate with the effectiveness of certain Tyrosine Kinase Inhibitors (TKI's) such as Gefitinib, Erlotinib, Afatinib, and Osimertinib against some Non-Small Cell Lung Cancers (NSCLCs). Activating mutations are reported to correlate with significant responses to such treatment, whilst certain other mutations correlate with resistance to first- and second-generation TKI's, but predict response to newer agents. EGFR mutation status is therefore vital in deciding the most appropriate treatment regime.
Please note tissue handling, tissue fixation, time between cutting and staining and excessive drying can lead to loss of expression. Fixatives containing alcohol should not be used and use of Bouin’s fixative will preclude testing by FISH methods.
A copy of the original Pathology report where possible.